Medicare announced this week that it would cover the costs for the Prostate Cancer drug Provenge. The drug can cost as much as $93,000 a patient. Although not a cure for the disease, it can extend survival by four months.
According to the National Institute of Health, over 217,000 new cases of prostate cancer were registered in the US in 2010. To make matters worse, prostate cancer research doesn’t receive even half the federal funding that breast cancer research does. It is good to see some funding come through for this terrible disease.
Source: LA Times
